1. Allergan, Inc. (156 from 2,284 patents)

2. Io Therapeutics, Inc. (63 from 72 patents)

3. Allergan Sales, Inc. (60 from 228 patents)

4. Dartmouth College (8 from 653 patents)

5. Other (6 from 831,952 patents)

6. The Johns Hopkins University (5 from 3,656 patents)

7. Allergen Sales, Inc. (3 from 4 patents)

8. Lo Therapeutics, Inc. (3 from 3 patents)

9. University of Texas System (1 from 5,386 patents)

10. City of Hope National Medical Center (1 from 13 patents)

1. 12383521 - Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists

2. 11793781 - Autoimmune disorder treatment using RXR agonists

3. 11786555 - RAR selective agonists in combination with immune modulators for cancer immunotherapy

4. 11779558 - Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

5. 11737996 - Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

6. 11690831 - Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones

7. 11690832 - Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones

8. 11648223 - Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy

9. 11648222 - Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer

10. 11576881 - Autoimmune disorder treatment using RXR agonists

11. 11547684 - Autoimmune disorder treatment using RXR agonists

12. 11517549 - Treatment of disease with esters of selective RXR agonists

13. 11246845 - Autoimmune disorder treatment using RXR agonists

14. 11166927 - Autoimmune disorder treatment using RXR agonists

15. 11065219 - Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones